At Fall Clinical 2026, the obesity specialist said she sees direct anti-inflammatory effects from the drugs and warned that benefits fade once patients stop taking them.
Recap by typeshit. Full story at Dermatology Times.
A retrospective study in Cureus looks back at how well once-weekly semaglutide worked, and how safe it was, for teenagers with obesity.
Presented at Sleep Europe 2026, both trials found retatrutide lowered the apnea-hypopnea index more than placebo, including in people with type 2 diabetes.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
Dr Bajekal flags that people on Mounjaro, semaglutide or Wegovy should talk it through with their doctor ahead of an operation.
Centre Daily Times looks at how peptides taken by mouth can get past the gut intact and reach specific spots in the body, a key hurdle for pill versions of these drugs.
Loading…